LFG
VRDN icon

Larson Financial Group’s Viridian Therapeutics VRDN Stock Holding History

Larson Financial Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18K Buy
922
+9
+1% +$267 ﹤0.01% 1906
2025
Q4 		$28.4K Sell
913
-1,494
-62% -$41K ﹤0.01% 1521
2025
Q3 		$51.9K Buy
+2,407
New +$43.4K ﹤0.01% 1145
2025
Q2 		– Sell
-8
Closed -$108 – 3510
2025
Q1 		$108 Buy
+8
New +$136 ﹤0.01% 2900

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Larson Financial Group's VRDN Position: Q1 2026 in Review

Larson Financial Group increased its Viridian Therapeutics (VRDN) stake by 0.99% in Q1 2026, buying an estimated $267 and bringing the position to 922 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #1906.

Larson Financial Group first reported a position in VRDN in Q1 2025 and has held it in 4 quarters since. The position peaked at $51.9K in Q3 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Larson Financial Group held 922 shares of Viridian Therapeutics worth $18K as of Q1 2026.
  • Larson Financial Group bought 9 Viridian Therapeutics shares in Q1 2026, an estimated $267.
  • Viridian Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #1906 holding.
  • Larson Financial Group first reported a position in Viridian Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Larson Financial Group's Viridian Therapeutics position peaked at $51.9K in Q3 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.